Smalleycoordinates the technical due diligence process as investments are evaluated. Colbert and other venture capital investors considered successful see more than half their investments lose money. Nordan is slightly more bullish. All this could spell backlash and setbacks for nanotechnology development. Luxs index differs in three ways from the others, Nordan explains. How venture capital firm uses its money depends on its investment philosophy. Forecasting established cash flow and earnings metrics is difficult due to the technical complexity and product uncertainty. The frontrunner seems to be NanoTex, despite its repeated claims that it has no IPO plans.

Many more, however, will be acquired, and even more will fail. When the Merrill Lynch index was widely criticized by other investors and many in the nanotech field for the criteria used to include companies. Not surprisingly, pundits have scrutinized the IPOs timing and importance. Valuing nanotech companies, especially the ones with more speculative business models, is difficult prospect. The aim is to give the investor way to examine the current performance of nanotechnology as its appearing across the economy and clarify the opportunities that are emerging from nanotech innovations, Feeney says.

The firm has been expanding to keep up with about potential deals every six months. Leff, Ph. D. Although investors believe that expectations are more realistic, valuations more sensible, and analyses more grounded, they still want to avoid bubble forming and then bursting. IN CONTRAST, momentum investors look for strong business plans, large potential markets, clear product and commercialization strategies, solid intellectual property positions, and good management around which companies can be built. Only about 10 have ever attracted venture capital, and just 10 of those have received more than one round of funding.

Platform technology, or pluripotent, companies have the potential to impact many sectors and present more complicated analyses. Three nanotechrelated companies did manage to launch IPOs in but with little fanfare. The investment syndicate included Harris & Harris, two powerenergy investors, and medical device venture capital firm. NGen provides secondstage funding to emerging businesses, and its portfolio includes companies. The firm has several major corporations as its limited partners and academic scientists as venture partners. If you can away with the same outcome with less capital on the front end, you are going to make bette.